Last reviewed · How we verify
Enamel Matrix Derivative application
Enamel Matrix Derivative promotes periodontal tissue regeneration by mimicking the natural proteins present during tooth development and stimulating the migration and differentiation of periodontal ligament cells.
Enamel Matrix Derivative promotes periodontal tissue regeneration by mimicking the natural proteins present during tooth development and stimulating the migration and differentiation of periodontal ligament cells. Used for Periodontal intrabony defects, Furcation defects, Alveolar bone loss associated with periodontitis.
At a glance
| Generic name | Enamel Matrix Derivative application |
|---|---|
| Sponsor | University of Pisa |
| Drug class | Biologic regenerative therapy |
| Target | Amelogenins and enamel matrix proteins (non-receptor mediated cell signaling) |
| Modality | Small molecule |
| Therapeutic area | Dentistry / Periodontics |
| Phase | Phase 3 |
Mechanism of action
EMD is an extract of porcine tooth buds containing amelogenins and other enamel matrix proteins that facilitate periodontal wound healing and regeneration. When applied to periodontal defects, it recruits undifferentiated mesenchymal cells to the defect site and promotes their differentiation into cementoblasts and osteoblasts, thereby supporting the formation of new cementum, periodontal ligament, and alveolar bone.
Approved indications
- Periodontal intrabony defects
- Furcation defects
- Alveolar bone loss associated with periodontitis
Common side effects
- Transient tooth sensitivity
- Mild inflammation at application site
- Temporary discomfort
Key clinical trials
- Flapless Periodontal Regeneration Using Hyaluronic Acid Versus Enamel Matrix Derivative (NA)
- Clinical and Radiographic Assessment of Efficacy of Modified Minimally Invasive SurgicalTechnique (M-MIST) Alone and Combined With Enamel Matrix Proteins and Ox-derived Bone Graft in the Treatment of Single Bone Defects Between Teeth. (NA)
- A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects (NA)
- Effectiveness of Hyaluronic Acid (hyaDENT BG® Gel) Compared With Enamel Matrix Proteins (Emdogain®) in the Treatment of Angular Bone Defects in Combination With a Xenograft (Bio-Oss Collagen®) (NA)
- Clinical Outcomes of Enamel Matrix Derivative and Connective Tissue Graft in Modified Coronally Advanced Tunnel (MCAT) (NA)
- Evaluation of Clinical and Radiological Outcomes Following the Treatment of Periodontal Intraosseous Defects Using Autogenous Tooth-derived Graft or Autogenous Bone Graft With Enamel Matrix Derivatives. A 12-month Randomized Controlled Clinical Trial. (NA)
- Effect of Enamel Matrix Derivative or Hyaluronic Acid on Non-Surgical Treatment of Peri-Implantitis (NA)
- Evaluation of Enamel Matrix Derivative as an Adjunct to Minimally Invasive Non-surgical Treatment of Intrabony Defects. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enamel Matrix Derivative application CI brief — competitive landscape report
- Enamel Matrix Derivative application updates RSS · CI watch RSS
- University of Pisa portfolio CI